JOP20210247A1 - علاج الصداع باستخدام أجسام مضادة لـ cgrp - Google Patents

علاج الصداع باستخدام أجسام مضادة لـ cgrp

Info

Publication number
JOP20210247A1
JOP20210247A1 JOP/2021/0247A JOP20210247A JOP20210247A1 JO P20210247 A1 JOP20210247 A1 JO P20210247A1 JO P20210247 A JOP20210247 A JO P20210247A JO P20210247 A1 JOP20210247 A1 JO P20210247A1
Authority
JO
Jordan
Prior art keywords
headache
treatment
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
JOP/2021/0247A
Other languages
English (en)
Inventor
Jeffrey T L Smith
Barbara Schaeffler
Roger K Cady
Lahar Mehta
Joseph Hirman
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20210247A1 publication Critical patent/JOP20210247A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

غير متوفر
JOP/2021/0247A 2019-05-02 2020-02-18 علاج الصداع باستخدام أجسام مضادة لـ cgrp JOP20210247A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies
PCT/US2020/018702 WO2020222892A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
JOP20210247A1 true JOP20210247A1 (ar) 2023-01-30

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0247A JOP20210247A1 (ar) 2019-05-02 2020-02-18 علاج الصداع باستخدام أجسام مضادة لـ cgrp

Country Status (17)

Country Link
US (1) US20220251178A1 (ar)
EP (1) EP3962522A4 (ar)
JP (1) JP2022533030A (ar)
KR (1) KR20220004053A (ar)
CN (1) CN113811326A (ar)
AU (1) AU2020267107A1 (ar)
BR (1) BR112020027063A2 (ar)
CA (1) CA3133571A1 (ar)
CL (1) CL2021002866A1 (ar)
DO (1) DOP2021000215A (ar)
EA (1) EA202192865A1 (ar)
IL (1) IL287759A (ar)
JO (1) JOP20210247A1 (ar)
MA (1) MA55815A (ar)
MX (1) MX2021013426A (ar)
SG (1) SG11202110637RA (ar)
WO (1) WO2020222892A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240049275A (ko) * 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료
WO2023042123A1 (en) 2021-09-15 2023-03-23 H. Lundbeck A/S Anti-cgrp antibody dosing and screening methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101965461B1 (ko) * 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
LT3495392T (lt) * 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
JP6568099B2 (ja) * 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
DOP2021000215A (es) 2021-11-21
EA202192865A1 (ru) 2022-02-14
MA55815A (fr) 2022-03-09
BR112020027063A2 (pt) 2021-11-16
JP2022533030A (ja) 2022-07-21
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
WO2020222892A1 (en) 2020-11-05
CA3133571A1 (en) 2020-11-05
CN113811326A (zh) 2021-12-17
IL287759A (en) 2022-01-01
AU2020267107A1 (en) 2021-10-07
EP3962522A1 (en) 2022-03-09
US20220251178A1 (en) 2022-08-11
KR20220004053A (ko) 2022-01-11
EP3962522A4 (en) 2023-07-19
CL2021002866A1 (es) 2022-06-17

Similar Documents

Publication Publication Date Title
MX2021008267A (es) Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2023010900A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
EA201892294A1 (ru) Антитела и композиции против tim-3
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
EP3964527A3 (en) Combination therapy for cancer
JOP20200309A1 (ar) أجسام مضادة لـ il-11
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
NZ762312A (en) Anti-pacap antibody
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.